Consequently, BCMA surface expression on MM cells is increased leading to a higher anti-tumor capacity of BCMA CAR T-cells, as well as improved cytokine production and proliferation in preclinical models (92). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.